 | Up a level |
Matsusaka, S; Cao, S; Hanna, D L; Sunakawa, Y; Ueno, M; Mizunuma, N; Zhang-Wu, Xiaxia; Yang, D; Ning, Y; Stintzing, S; Sebio, A; Stremitzer, S; Yamauchi, S; Parekh, A; Okazaki, S; Berger, Martin Dave; El-Khoueiry, R; Mendez, A; Ichikawa, W; Loupakis, F; ... (2017). CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics journal, 17(6), pp. 543-550. Nature Publishing Group 10.1038/tpj.2016.59
Berger, Martin Dave; Stintzing, S; Heinemann, V; Yang, D; Cao, S; Sunakawa, Y; Ning, Y; Matsusaka, S; Okazaki, S; Miyamoto, Y; Suenaga, M; Schirripa, M; Soni, S; Zhang, W; Falcone, A; Loupakis, F; Lenz, H-J (2017). Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of oncology, 28(11), pp. 2780-2785. Oxford University Press 10.1093/annonc/mdx412
Suenaga, M; Schirripa, M; Cao, S; Zhang-Wu, Xiaxia; Yang, D; Murgioni, S; Rossini, D; Marmorino, F; Mennitto, A; Ning, Y; Okazaki, S; Berger, Martin Dave; Miyamoto, Y; Gopez, R; Barzi, A; Yamaguchi, T; Loupakis, F; Lenz, H-J (2017). Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Annals of oncology, 28(5), pp. 1015-1022. Oxford University Press 10.1093/annonc/mdx035
